Clinical Trial Update: Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium [Phase 2]

View source ↗

Summary

Phase 2 trial update of buparlisib in metastatic transitional cell carcinoma of the urothelium completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma of the Urothelium

Drugs mentioned

• Buparlisib (buparlisib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Transitional Cell Carcinoma of the Urothelium | Phase 2 | Status: COMPLETED | Results posted: 2021-06-21